SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

Published: 31 August 2022

  • Views:

    Views Icon 50994

  • Likes:

    Heart Icon 7
  • episode_image
    15 min
    Part 5 Q&A and Discussion
    Scott Solomon, John JV McMurray, Carolyn Lam, Muthiah Vaduganathan
Average (ratings)
No ratings
Your rating

Overview

During this unique broadcast, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’, Radcliffe Medical Education brings together a globally-renowned faculty to participate in a discussion centred around the presentation of the latest SGLT-2 inhibition data and how this translates to the treatment of Heart Failure patients.

 

Presented, and recorded, at ESC Congress 2022 in Barcelona, this programme is now available to watch on-demand. The programme is chaired by Prof Scott Solomon (Boston, US), who is joined by Prof John McMurray (Glasgow, UK), Prof Carolyn Lam (Singapore, SG) and Dr Muthiah Vaduganathan (Boston, US) while they explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice. 

 

This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.

 

 

CME accredited version available here
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.

Learning Objectives

Upon participation in this programme, physicians will be able to:

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF

This programme is intended to educate:

  • Global cardiologists
  • Heart Failure specialists
  • Primary care physicians
  • Nurses
  • Pharmacists

More from this programme

Part 1

SGLT2 Inhibitors - Another piece of the Puzzle in Heart Failure

1 session
SGLT2 Inhibitors: Light at the End of the Tunnel Watch now

Part 2

SGLT2 Inhibitors Across the Spectrum of Heart Failure

1 session
SGLT2 Inhibitors Across the Spectrum of Heart Failure Watch now

Part 3

Practical Considerations for Treating HF With Mildly Reduced and Preserved EP

1 session
Practical Considerations for Treating HF With Mildly Reduced and preserved EF Watch now

Part 4

Implementing Best Practices Across the Spectrum of Heart Failure

1 session
Implementing Best Practices Across the Spectrum of Heart Failure Watch now

Part 5

Q&A and Discussion

1 session
Q&A and Discussion Watch now

Faculty Biographies

Muthiah Vaduganathan

Muthiah Vaduganathan

Consultant Cardiologist

Dr Vaduganathan is a Cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He is a co-chair of a Heart Failure Collaboratory committee focused on improving future clinical trials in heart failure, and serves on the planning committee of the Global CardioVascular Clinical Trialists Forum. He is a Section Editor of the Fellows-in-Training / Early Career section of JACC, Associate Editor of JACC Heart Failure, and serves on the editorial board of the European Journal of Heart Failure. His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies, and he has authored or co-authored more than 500 peer-reviewed publications. He participates on study leadership and on committees of ongoing advanced-phase trials in cardiometabolic medicine and heart failure.…

View full profile